-
-
-
-
-
-
-
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
-
-
-
-
-
-
-
FDA accepts rusfertide application with priority review for blood disorder
-
-
-
-
-
-
-
Takeda launches GAMMAGARD LIQUID ERC immunoglobulin therapy in US
-
-
-
-
-
-
-
Protagonist and Takeda report 52-week rusfertide data in polycythemia vera
-
-
-
-
-
-
-
HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
-
-
-
-
-
-
-
Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit
-
-
-
-
-
-
-
Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration
-
1,165,899 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

